Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901

The development of efficient immunotherapies requires strong rationalization. We have recently implemented an extensive analysis of biomarkers in two studies involving the multi-peptide vaccine IMA901 and advanced renal cell cancer patients. Our findings demonstrate that the breadth of immune responses was associated with a clinical benefit and that single-dose cyclophosphamide reduced the amount of regulatory T cells and was associated with prolonged survival after vaccination.